Bonafide Health Launches Hormone-Free Supplement for Menopause-Related Sleep Disturbances

Bonafide Health, LLC has expanded its portfolio of menopause-focused supplements with the launch of Noctera, a hormone-free, melatonin-free formulation designed to improve sleep quality and duration in women experiencing hormonal changes, states a February press release from the company.¹

Noctera’s mechanism of action

According to a study published in the Journal of Menopausal Medicine, sleep disturbances are among the most frequently reported symptoms in women aged 40–64, often driven by fluctuations and eventual declines in estrogen.² Symptoms reported include difficulty falling asleep, staying asleep, and waking the in the early morning. According to Alyssa Dweck, MS, MD, FACOG, MSCP, chief medical officer at Bonafide and co-author of the company’s clinical research, estrogen is significant in various functions. “Estrogen plays a critical role in how our brain regulates temperature, sleep, and mood,” she explains. "Declining estrogen levels during the menopause transition affect the balance of both GABA, a calming neurotransmitter in the brain and Glutamate, an excitatory one. This imbalance has direct effects on sleep, specifically associated with the frequent nocturnal awakenings and difficulty falling back asleep during this time of life.”

Noctera is positioned as a non-sedative dietary supplement formulated to address these mechanisms. The product features four key ingredients: magnesium glycinate, GABA, L-theanine, and S-adenosylmethionine (SAMe). Magnesium glycinate and L-theanine are included to help modulate excitatory signaling, while GABA is intended to promote relaxation and calm what the company describes as the “busy mind.” SAMe is incorporated to further support neurotransmitter balance and sleep regulation. The formula utilizes a continuous-release delivery system designed to provide sustained support throughout the night and improve energy during the daytime. The supplement is also described as safe for daily use, and is available on Bonafide’s website and on Amazon, the press release states.

Clinical study results

Findings from a randomized, double-blind, placebo-controlled trial evaluating the supplement in perimenopausal and postmenopausal women were presented in an abstract published in Sleep in May 2025. In the study, titled “Effect of a Nonhormonal Sleep Supplement on Sleep Quality in Peri- and Postmenopausal Females,” investigators assessed sleep disturbances using PROMIS-SD T-scores, a patient-reported outcomes measure.²

As Bonafide Health highlights, 88% of women with moderate-to-severe sleep disturbances experienced reductions that moved their scores “within normal limits” within three weeks of supplementation. Participants also demonstrated an average increase in sleep duration of approximately 40 minutes. Additionally, 89% of women reported improved ability to fall back asleep after nighttime awakenings when using the supplement as directed. Secondary outcomes included reported improvements in morning grogginess, ease of getting out of bed, daytime sleepiness, and overall sleep satisfaction. The study reported a favorable safety profile, with no significant adverse events observed.

Company mission and expansion

Bonafide reports partnerships with FDA-registered, GMP-certified manufacturing facilities and states that products undergo rigorous testing for quality, purity, and potency. The company states its mission is to continue to build a portfolio of clinically researched and effective solutions targeting symptoms associated with perimenopause and menopause.

In late 2023, Bonafide Health was acquired by Pharmavite LLC, in a move seen as expanding the reach of its products. “Our steadfast commitment to science and innovation has allowed us to build something special at Bonafide Health and we’ve been looking for the right partner to grow the business and reach more women that need support. Pharmavite is that partner,” Michael Satow co-founder and CEO of Bonafide Health, had explained in a press release.³ “Pharmavite deeply understands the importance of the model we’ve built, from the rigorous scientific data that underpins our products, to the power of the work we do with the doctors and other health care providers who are having conversations with women across the country looking for better solutions.”

This article was created with assistance from AI. The content has been reviewed and edited by Erin McEvoy, Associate Editor. For more information on the extent and nature of AI usage, please contact us.

References

1. Bonafide Health. Bonafide® Health Launches NocteraTM – A Novel, Hormone-Free Supplement Designed to Improve Sleep Quality and Duration Negatively Impacted by Hormonal Changes. Published February 19, 2026. Accessed February 23, 2026.
2. Lee J, Han Y, Cho HH, Kim MR. Sleep Disorders and Menopause. J Menopausal Med. 2019 Aug;25(2):83-87. doi: 10.6118/jmm.19192.
3. Krawiec, S. Pharmavite acquires Bonafide Health, a women’s health brand that focuses on menopause support. Published December 1, 2023. Accessed February 23, 2026. https://www.nutritionaloutlook.com/view/pharmavite-acquires-bonafide-health-a-women-s-health-brand-that-focuses-on-menopause-support